# A Phase I Multicentre Randomized Double-Blind Parallel-Controlled Study of HLX05-N vs. ERBITUX® in Metastatic Colorectal Cancer

> **NCT07543471** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Shanghai Henlius Biotech** · enrollment: 387 (estimated)

## Conditions studied

- mCRC

## Interventions

- **DRUG:** Cetuximab
- **DRUG:** mFOLFOX6

## Key facts

- **NCT ID:** NCT07543471
- **Lead sponsor:** Shanghai Henlius Biotech
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-06-30
- **Primary completion:** 2027-06-30
- **Final completion:** 2028-04-30
- **Target enrollment:** 387 (ESTIMATED)
- **Last updated:** 2026-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07543471

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07543471, "A Phase I Multicentre Randomized Double-Blind Parallel-Controlled Study of HLX05-N vs. ERBITUX® in Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07543471. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*